Compare RECT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RECT | BCDA |
|---|---|---|
| Founded | 1997 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 15.7M |
| IPO Year | 2023 | 2009 |
| Metric | RECT | BCDA |
|---|---|---|
| Price | $1.27 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 4.6K | ★ 114.1K |
| Earning Date | 07-30-2026 | 11-16-2026 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.96 | $0.75 |
| 52 Week High | $2.90 | $1.80 |
| Indicator | RECT | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 44.86 |
| Support Level | $1.07 | $0.82 |
| Resistance Level | $1.39 | $1.06 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 22.67 | 29.33 |
Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks. Additionally the company has added auxiliary products such as industrial hardware tools and electrical hardware required for construction sites.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).